Approval of Merck's oral PCSK9 inhibitor LIPFENDRA and emerging oral competitors signal a high‑growth phase for the PCSK9 inhibitor market
Executive summary: Merck's oral PCSK9 inhibitor LIPFENDRA was approved and other oral PCSK9 inhibitors (AZD0780, AQR-008) are emerging, pushing the market into a high‑growth phase. Oral formulations could improve patient adherence and expand the addressable population for LDL‑C‑lowering therapy, challenging the current injectable‑dominant landscape.
Who is involved: Merck, AstraZeneca, Aqur, DelveInsight (market analyst), and patients with hypercholesterolemia or cardiovascular disease.
Likely next: Market uptake of the new oral agents will be monitored over the next 12‑18 months, with potential further approvals and label expansions for cardiovascular outcomes.
The press release highlights that Merck’s LIPFENDRA has received regulatory approval, joining a wave of oral PCSK9‑inhibitor candidates such as AstraZeneca’s AZD0780 and Aqur’s AQR‑008. This shift from injectable to oral dosing is expected to improve patient adherence and broaden the treatable population for LDL‑C lowering. DelveInsight projects that these developments will drive robust expansion of the PCSK9 inhibitor market amid rising global hypercholesterolemia and cardiovascular disease prevalence.
Timeline
- — The Oral PCSK9 Inhibitor Market Enters High-Growth Phase Owing to the Approval of Merck's LIPFENDRA and the Emergence of Oral PCSK9 Inhibitor Drugs, Including, AstraZeneca's AZD0780, Aqur's AQR-008, and Others | DelveInsight (PR Newswire)
Analysis — what this means
Sectors affected
- Cardiovascular lipid‑lowering therapy market
Key entities
Sources
Open the full interactive case file on Beyond →